TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Voprosy Sovremennoj Pediatrii. 2011;10(3)

 

Journal Homepage

Journal Title: Voprosy Sovremennoj Pediatrii

ISSN: 1682-5527 (Print); 1682-5535 (Online)

Publisher: "Paediatrician" Publishers LLC

Society/Institution: The Union of Pediatricians of Russia

LCC Subject Category: Medicine: Pediatrics

Country of publisher: Russian Federation

Language of fulltext: English, Russian

Full-text formats available: PDF

 

AUTHORS

E.I. Alexeeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow I.M. Sechenov First Moscow State Medical University)
R.V. Denisova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
S.I. Valieva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
T.M. Bzarova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
K.B. Isaeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.G. Chistyakova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow I.M. Sechenov First Moscow State Medical University)
T.V. Sleptsova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.V. Mitenko (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 8 weeks

 

Abstract | Full Text

<em>This article contains results of the research of tocilizumab treatment efficacy and safety in 39 patients with severe systemic juvenile idiopathic arthritis, resistant to standard immunosuppressive treatment. Tocilizumab efficacy analysis has shown 50% of patients with inactive disease after 6 months of treatment, and 57% of patients with inactive disease after 12 months. Among adverse events were mild and moderate infections and such laboratory abnormalities as low leukocyte and neutrophiles count.</em><br /><strong><em>Key words: children, juvenile idiopathic arthritis, systemic arthritis, tocilizumab, treatment.</em></strong><br /><span style="text-decoration: underline;"><em><em><em>(Voprosy sovremennoi pediatrii — Current Pediatrics. </em></em></em><em><em><em>2011; 10 (3): 24–32)</em></em></em></span>